Kiora's investigational treatment for retinitis pigmentosa, KIO-301, demonstrates visual function restoration in patients who are blind
Figure 1. Functional MRI images of the brain visual cortex of patient treated with KIO-301 (from visit one to visit five), and reference image showing striate V1, V2 and V3 regions. Credit: Kiora Pharmaceuticals
Additional Media
Patient interview as part of the ABACUS study of KIO-301 for the treatment of retinitis pigmentosa. Credit: Kiora
Simulation of vision through the eyes of a patient living with retinitis pigmentosa. Credit: Kiora Pharmaceuticals
Keywords
Contact Information
Source
How to Cite This Article
APA:
Kiora Pharmaceuticals. (2023, April 27). Kiora's investigational treatment for retinitis pigmentosa, KIO-301, demonstrates visual function restoration in patients who are blind. Brightsurf News. https://www.brightsurf.com/news/LQ423Y68/kioras-investigational-treatment-for-retinitis-pigmentosa-kio-301-demonstrates-visual-function-restoration-in-patients-who-are-blind.html
MLA:
"Kiora's investigational treatment for retinitis pigmentosa, KIO-301, demonstrates visual function restoration in patients who are blind." Brightsurf News, Apr. 27 2023, https://www.brightsurf.com/news/LQ423Y68/kioras-investigational-treatment-for-retinitis-pigmentosa-kio-301-demonstrates-visual-function-restoration-in-patients-who-are-blind.html.